[{"address1": "121 Richmond Street West", "address2": "Penthouse Suite, 1300", "city": "Toronto", "state": "ON", "zip": "M5H2K1", "country": "Canada", "phone": "416 346 7764", "website": "https://www.psyencebiomed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jody  Aufrichtig", "age": 51, "title": "Co-Founder, Executive Chairman & CEO", "yearBorn": 1974, "fiscalYear": 2025, "totalPay": 216667, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Warwick Ron Corden-Lloyd", "age": 45, "title": "CFO & Director", "yearBorn": 1980, "fiscalYear": 2025, "totalPay": 195000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neil  Maresky M.D.", "age": 61, "title": "Global Head of Clinical Development", "yearBorn": 1964, "fiscalYear": 2025, "totalPay": 390000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Taryn  Vos", "title": "General Counsel", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.6701, "open": 0.6882, "dayLow": 0.615, "dayHigh": 0.69, "regularMarketPreviousClose": 0.6701, "regularMarketOpen": 0.6882, "regularMarketDayLow": 0.615, "regularMarketDayHigh": 0.69, "payoutRatio": 0.0, "beta": 0.318, "volume": 495403, "regularMarketVolume": 495403, "averageVolume": 1391104, "averageVolume10days": 337630, "averageDailyVolume10Day": 337630, "bid": 0.6311, "ask": 0.6896, "bidSize": 1, "askSize": 1, "marketCap": 4280365, "fiftyTwoWeekLow": 0.615, "fiftyTwoWeekHigh": 17.44, "allTimeHigh": 8730.0, "allTimeLow": 0.615, "fiftyDayAverage": 1.52928, "twoHundredDayAverage": 3.560665, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -5895711, "profitMargins": 0.0, "floatShares": 1550489, "sharesOutstanding": 6388604, "sharesShort": 18193, "sharesShortPriorMonth": 16358, "sharesShortPreviousMonthDate": 1764288000, "dateShortInterest": 1767139200, "sharesPercentSharesOut": 0.0097, "heldPercentInsiders": 0.04913, "heldPercentInstitutions": 0.029409999, "shortRatio": 0.04, "shortPercentOfFloat": 0.0097, "impliedSharesOutstanding": 6388605, "bookValue": 6.339, "priceToBook": 0.105694905, "lastFiscalYearEnd": 1743379200, "nextFiscalYearEnd": 1774915200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -3941597, "trailingEps": -389.98, "lastSplitFactor": "125:1000", "lastSplitDate": 1746403200, "enterpriseToEbitda": 1.422, "52WeekChange": -0.95130813, "SandP52WeekChange": 0.14725316, "quoteType": "EQUITY", "currentPrice": 0.67, "recommendationKey": "none", "totalCash": 7149985, "totalCashPerShare": 3.819, "ebitda": -4145455, "totalDebt": 0, "quickRatio": 7.766, "currentRatio": 8.09, "returnOnAssets": -0.34442002, "returnOnEquity": -0.74286, "freeCashflow": -4006023, "operatingCashflow": -4247508, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "PBM", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Psyence Biomedical Ltd.", "longName": "Psyence Biomedical Ltd.", "regularMarketChangePercent": -0.0149167, "regularMarketPrice": 0.67, "corporateActions": [{"header": "Reverse stock split", "message": "PBM announces 1 for 6.25 split effective Jan. 20, 2026", "meta": {"eventType": "SPLIT", "dateEpochMs": 1768885200000, "splitRatio": "1:6.25"}}], "postMarketTime": 1768610999, "regularMarketTime": 1768597201, "exchange": "NCM", "messageBoardId": "finmb_698500412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1639146600000, "postMarketChangePercent": 1.6268598, "postMarketPrice": 0.6809, "postMarketChange": 0.010899961, "regularMarketChange": -9.9957e-05, "regularMarketDayRange": "0.615 - 0.69", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1391104, "fiftyTwoWeekLowChange": 0.055000007, "fiftyTwoWeekLowChangePercent": 0.089430906, "fiftyTwoWeekRange": "0.615 - 17.44", "fiftyTwoWeekHighChange": -16.77, "fiftyTwoWeekHighChangePercent": -0.96158254, "fiftyTwoWeekChangePercent": -95.13081, "epsTrailingTwelveMonths": -389.98, "fiftyDayAverageChange": -0.85927993, "fiftyDayAverageChangePercent": -0.5618853, "twoHundredDayAverageChange": -2.8906648, "twoHundredDayAverageChangePercent": -0.81183285, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2024-01-26", "prevName": "Psyence Therapeutics Corp.", "nameChangeDate": "2026-01-16", "cryptoTradeable": false, "displayName": "Psyence Biomedical", "trailingPegRatio": null, "__fetch_time": "2026-01-17"}]